spinal ependymoma
Conditions
Interventions
Group 1: Surgical treatment +/- adjuvant treatment (radiotherapy, chemotherapy)
Sponsors
Universitätsklinikum Regensburg, Neurochiurgische Klinik und Poliklinik
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with histologically confirmed spinal ependymoma (WHO grades 2–3), Availability of complete clinical, neuropathological, surgical, and follow-up data.
Exclusion criteria
Exclusion criteria: Unavailability of complete clinical, neuropathological, surgical, and follow-up data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Impact of extent of resection / tumor genetics on overall survival (+/- ambulatory functioning), Composite primary endpoint: Time to event (defined as either death or deterioration to modified McCormick grade 3-5) | — |
Secondary
| Measure | Time frame |
|---|---|
| Imaging features predictive of outcomes, Efficacy and role of 5-ALA/Na-fluorescein use in extent of resection, Role of extent of resection regarding OS, PFS, and neurological functioning, Correlation of molecular markers (e.g. myc-n) with clinical outcomes, Neurological outcomes post-surgery (e.g. modified McCormick), Efficacy and safety of adjuvant therapies (radiotherapy, chemotherapy) | — |
Countries
Germany
Contacts
Public ContactSebastian Siller
Universitätsklinikum Regensburg, Neurochirurgische Klinik und Poliklinik
Outcome results
None listed